Getein Biotech, Inc (SHA:603387)
China · Delayed Price · Currency is CNY 9.09
-0.25 (-2.68%)
May 21, 2026, 3:00 PM CST
Getein Biotech Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 223.92 | 211.92 | 223.64 | 279.77 | 498.91 | 398.99 |
Depreciation & Amortization | 85.36 | 85.36 | 92.29 | 93.08 | 70.35 | 49.4 |
Other Amortization | 4.05 | 4.05 | 7.16 | 8.77 | 7.79 | 7.13 |
Loss (Gain) From Sale of Assets | 0.05 | 0.05 | -1.59 | -0.67 | -0.02 | -1.05 |
Asset Writedown & Restructuring Costs | 2.8 | 2.8 | 31.15 | 1.69 | 0.53 | 0.1 |
Loss (Gain) From Sale of Investments | 8.71 | 8.71 | -2.27 | -26.31 | -34.63 | -23.56 |
Provision & Write-off of Bad Debts | - | - | 13.7 | 19.21 | 22.87 | 8.36 |
Other Operating Activities | 35.6 | 23.78 | 7.11 | 29.77 | 37.37 | 31.26 |
Change in Accounts Receivable | 30.39 | 30.39 | 23.66 | -2.45 | -111.25 | -49.52 |
Change in Inventory | -0.12 | -0.12 | 3.9 | 17.34 | -52.25 | -43.27 |
Change in Accounts Payable | 34.63 | 34.63 | 30.24 | -81.06 | 53.6 | 56.13 |
Operating Cash Flow | 416.41 | 392.59 | 423 | 333.22 | 482.96 | 432.36 |
Operating Cash Flow Growth | 2.89% | -7.19% | 26.94% | -31.00% | 11.70% | 133.12% |
Capital Expenditures | -135.16 | -150.58 | -156.4 | -258.13 | -217.44 | -179.6 |
Sale of Property, Plant & Equipment | 4.28 | 4.39 | 5.25 | 8.65 | 4.57 | 2.87 |
Cash Acquisitions | -1.57 | -1.57 | - | - | - | - |
Divestitures | 1.35 | 1.35 | 1.58 | 3.23 | - | - |
Investment in Securities | 22.82 | -53.75 | -153.08 | -119.8 | -586.57 | -104.75 |
Other Investing Activities | -7.54 | -14.6 | -45.47 | 9.22 | 39 | 26.84 |
Investing Cash Flow | -115.83 | -214.76 | -348.12 | -356.83 | -760.44 | -254.63 |
Long-Term Debt Issued | - | 779.5 | 1,070 | 1,130 | 792.44 | 496.63 |
Total Debt Issued | 474.48 | 779.5 | 1,070 | 1,130 | 792.44 | 496.63 |
Long-Term Debt Repaid | - | -880.53 | -1,156 | -1,062 | -707.06 | -380.89 |
Net Debt Issued (Repaid) | -203.06 | -101.03 | -85.64 | 67.92 | 85.39 | 115.74 |
Repurchase of Common Stock | - | - | - | - | - | -50.38 |
Common Dividends Paid | -103.41 | -103.24 | -110.98 | -219.4 | -140.73 | -103.57 |
Other Financing Activities | -6.97 | -7.29 | -17.05 | 5.61 | 9.46 | 9.28 |
Financing Cash Flow | -313.44 | -211.56 | -213.67 | -145.88 | -45.88 | -28.93 |
Foreign Exchange Rate Adjustments | -9.71 | -7.39 | 5.89 | 11.67 | 19.2 | -1.02 |
Net Cash Flow | -22.57 | -41.12 | -132.89 | -157.81 | -304.16 | 147.78 |
Free Cash Flow | 281.25 | 242.01 | 266.6 | 75.09 | 265.51 | 252.77 |
Free Cash Flow Growth | 17.90% | -9.22% | 255.02% | -71.72% | 5.04% | 251.38% |
Free Cash Flow Margin | 26.16% | 23.01% | 22.89% | 5.49% | 14.57% | 18.03% |
Free Cash Flow Per Share | 0.56 | 0.48 | 0.53 | 0.15 | 0.52 | 0.49 |
Cash Income Tax Paid | 89.94 | 89.94 | 91.25 | 148.48 | 123.19 | 148.32 |
Levered Free Cash Flow | 193.46 | -105.7 | 474.7 | -66.49 | -269.29 | 115.56 |
Unlevered Free Cash Flow | 195.09 | -105.7 | 484.03 | -55.9 | -258.91 | 124.51 |
Change in Working Capital | 55.93 | 55.93 | 51.82 | -72.09 | -120.22 | -38.26 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.